Videos

Dr. Jennifer Payne discusses how the events of the last year has impacted her patients and what needs to happen to improve mental health care in the future.

Insight on the screening and monitoring for red blood cell transfusion for the management of sickle cell disease.

Wally Smith, MD, discusses L-glutamine in the treatment of SCD.

Henry Nasrallah, MD, compares the European Guidelines and United States Guidelines; the panel discusses guidelines currently in place for psychiatric patients.

Joe Avelino, RN, BSN, MHSA, CPHQ, defines a hospital versus an institution; and Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the lack of guideline-supported protocols for patients

Experts share insights on how they have utilized Prescription Monitoring Programs to combat the opioid crisis and improve the safety of prescribed opioids.

Experts share approaches to normalize conversations about naloxone with patients, as well as share important considerations for maximizing naloxone education.

ABX464 is being tested for numerous indications, including ulcerative colitis.

Common organs impacted by inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis and recommendations for assessing disease severity when diagnosing patients.

Norman Lepor, MD, FACC, FAHA, FSCAI, reviews the efficacy of inclisiran in terms of LDL reduction based on the pooled analysis of the phase 3 ORION trials.

Experts review in detail the emerging use of inclisiran as an adjunct therapy for lipid lowering in patients with high cholesterol.

A review of the safety and efficacy of systemic agents such as methotrexate, azathioprine, and cyclosporine in patients with severe, persistent atopic dermatitis.

Experts in the management of atopic dermatitis review the safety and efficacy of topical calcineurin inhibitors and topical PDE4 inhibitors.

Contraindications for clinicians to keep in mind when administering sacubitril/valsartan therapy, and an examination of target dose for therapies in heart failure with reduced ejection fraction.

Considerations for initiating sacubitril/valsartan as de novo therapy in patients naïve to angiotensin-converting enzyme inhibitors or angiotensin receptor blocker therapies as per the 2021 update of the expert consensus decision pathway document.

A thrombosis expert details cerebral venous thrombosis, the side effect reported in a half-dozen women administered the Johnson & Johnson vaccine.

Patrick McGann, MD, MS, reviews the role of hydroxyurea in sickle cell disease, touching on the mechanism of action and expected outcomes.

Clinicians dive into the impact of sickle cell on quality of life and symptom management

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, review how early long-acting injectables should be started in patients with schizophrenia.

Henry Nasrallah, MD, and Rahn Bailey, MD, DFAPA, discuss how to switch a patient from oral to a long-acting injectable antipsychotic from their own experience.

Multidisciplinary panel of clinicians discuss whether recommendations made by national, state, and local agencies infringes upon clinical practice autonomy. 

Jeffrey Bratberg, PharmD, FAPhA, and Joshua Lynch, DO, EMT-P, FAAEM, FACEP, discuss highlights from the December 2020 CDC Health Alert and application.

Panel of experts discuss the use and safety profile of purified icosapent ethyl compound (EPA) in prevention of CV risk.

Cardiologists briefly review the outcomes data and practical implications of novel treatment options for hyperlipidemia.

Peter Lio, MD, and Elizabeth Swanson, MD, provide insight on using nonpharmacological therapies and state-of-the-art skin care treatments for patients with atopic dermatitis.

Patient factors considered when prescribing treatment options for the management of atopic dermatitis.

A discussion on the safety and efficacy of angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, for the treatment of heart failure.

Experts in cardiology provide a brief history on treatments used for heart failure including ACE (angiotensin converting enzyme) inhibitors and beta blockers.